iktos

Since its inception, iktos is pushing hard the limits to bring AI solutions for new drug design. This has been highlighted in the Japanese book « Handbook of Pharmaceutical Affairs 2024 », which reports the summary of pharmaceutical administration and pharmaceutical industry topics and trends. In this book, authors report that Iktos is ranked #2 among AI companies in the number of partnership agreements, having partnered with 7 pharmaceutical companies. For more information: https://lnkd.in/ees5NN5x Big congratulations to our colleague Hideyoshi Fuji, who has been instrumental in this achievement! As part of our trustful Japanese partners we can name Teijin Limited, ONO PHARMACEUTICAL CO., LTD., Kissei Pharmaceutical Co Ltd, within a list that keeps growing.

It was tough and stressful but he did it! Just a few days ago our colleague Franck Le Vaillant has won the World champion title of land sailing ! The whole iktos team is very proud of him for such a career accomplishment, this is fantastic! 👏 👏 👏 Big congratulations to him for bringing back the title home!! 🏆🏆🏆 Photos credit: Camille Béglin

Planning to attend the 39th Interactive Seminar for Novel Medicinal Sciences in Nagano, Japan on July 10-12 2024? Do not miss Hideyoshi Fuji presentation and meet with our colleague Victoire M. L. Cachoux. This seminar, organized by the Pharmaceutical Society of Japan, is the perfect place to gather researchers from industry, government, and academia around drug discovery topics and discussions. The iktos team looks forward to meeting with you there. 👉 To learn more: https://lnkd.in/e6hgVQHK

🚨 Breaking news 🚨 iktos acquires SYNSIGHT, a life sciences technology company specializing in protein-protein and RNA-protein interactions-targeted drug discovery. As Yann Gaston-Mathe, CEO and Co-founder of Iktos comments « The acquisition of Synsight enables Iktos to expand its platform to new modulators of Protein-Protein interaction’s and RNA-Protein Interaction’s, historically highly challenging targets, thereby addressing major unmet medical needs in various therapeutic areas such as cancer and neurodegenerative diseases » The merger further complements Iktos' AI-based drug discovery platform, that currently includes generative AI design, Retrosynthesis, and AI-driven automated synthesis capabilities by adding the key step of automated biological testing thanks to MT Bench technology originally developed at INSERM. 👉 To learn more about this acquisition: https://lnkd.in/ez7hHmM8 #drugdiscovery #artificialintelligence #proteinproteininteractions #RNAinteractions Genopole Medicen Paris Region

Planning to attend the Clarivate for Life Sciences & Healthcare 2024 conference on the potential of AI in Drug Development on July 4th in Tokyo? If so, do not miss the keynote speech from iktos representative Director in Japan, Hideyoshi Fuji. He will talk about « Innovative AI Drug Discovery Using Generative AI and Robotics » ! 👉 Please learn more here: https://lnkd.in/e-kYQQr4

The 38th ACS National Medicinal Chemistry Symposium in Seattle, WA continues with another exciting day! Please meet with Philip Laut and Brian Atwood at our booth and discover how iktos can help in your drug discovery projects. https://www.nmcsmedi.org/ #ACS #NMCS #artificialintelligence #Makya #Spaya #Robotics #medicinalchemistry

👏👏👏 Congratulation to our fantastic teammate Franck Le Vaillant!! Besides being Senior Scientist and Deputy Lab Head at iktos, Franck is a true athlete who just won the title of French Land Sailing Champion! The whole Iktos members teamed up with him and are very proud of him! Next step: the World Land Sailing Championship in 10 days! We wish Franck all the best, with the endurance and the success for what could be an unbelievable milestone to his prize list! 🏆 💪 Let's go Franck!!

We are thrilled to announce our collaboration with ITALFARMACO S.P.A., an Italian multinational pharmaceutical leader to develop next generation histone deacetylase (HDAC) for a variety of non-oncological diseases, including diseases affecting the central nervous system. Our commitment at iktos lies in advancing innovative technologies that augment the likelihood of success in small molecule discovery. Please learn more about this collaboration: https://lnkd.in/eUSryh_q   #Italfarmaco #Iktos #robotics #medicinalchemistry #drugdiscovery #artificialintelligence #AI 

Learn more from two main architects behind Elsevier and iktos multi-year partnership recently announced. In this fireside chat, Yann Gaston-Mathe, CEO and co-founder of Iktos and Abhinav Kumar, Reaxys Innovation Director, share their common vision on their work, mission and why it makes sense for the two organizations to partner together. 👉 https://lnkd.in/e5U-bzwb

Notre CEO Yann Gaston-Mathe sera à l’Onco Startup Summit demain à Paris ! LE rv des startups en oncologie pendant le Congrès IFODS 🔎 17h - Comment l’IA peut accélérer le développement des innovations des startups de l’oncologie ? 👉Programme complet : https://lnkd.in/eNU2qxUs